FDA requests more information from Avedro in corneal cross-linking NDA

Healio

Avedro Inc. announced it plans on working closely with the U.S. Food and Drug Administration to answer the organization’s questions on its New Drug Application for the riboflavin ophthalmic solution/KXL System.

  • <<
  • >>

Comments